Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 232

1.

PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.

Guyot E, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, Ganne-Carrié N, Beaugrand M, Charnaux N, Trinchet JC, Nahon P.

J Hepatol. 2013 Feb;58(2):312-8. doi: 10.1016/j.jhep.2012.09.036. Epub 2012 Oct 13.

PMID:
23069476
2.

The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis.

Nischalke HD, Berger C, Luda C, Berg T, Müller T, Grünhage F, Lammert F, Coenen M, Krämer B, Körner C, Vidovic N, Oldenburg J, Nattermann J, Sauerbruch T, Spengler U.

PLoS One. 2011;6(11):e27087. doi: 10.1371/journal.pone.0027087. Epub 2011 Nov 7.

3.

PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.

Falleti E, Fabris C, Cmet S, Cussigh A, Bitetto D, Fontanini E, Fornasiere E, Bignulin S, Fumolo E, Bignulin E, Pirisi M, Toniutto P.

Liver Int. 2011 Sep;31(8):1137-43. doi: 10.1111/j.1478-3231.2011.02534.x. Epub 2011 Apr 19.

PMID:
21745286
4.

Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus-related cirrhosis.

Charni F, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, Ganne-Carrié N, Trinchet JC, Beaugrand M, Charnaux N, Nahon P.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1439-46. doi: 10.1158/1055-9965.EPI-11-0341. Epub 2011 May 24.

5.

Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, Day CP, Daly AK, Reeves HL, Anstee QM.

J Hepatol. 2014 Jul;61(1):75-81. doi: 10.1016/j.jhep.2014.02.030. Epub 2014 Mar 6.

PMID:
24607626
6.

The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis.

Takeuchi Y, Ikeda F, Moritou Y, Hagihara H, Yasunaka T, Kuwaki K, Miyake Y, Ohnishi H, Nakamura S, Shiraha H, Takaki A, Iwasaki Y, Nouso K, Yamamoto K.

J Gastroenterol. 2013 Mar;48(3):405-12. doi: 10.1007/s00535-012-0647-3. Epub 2012 Aug 7.

7.

Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.

N'Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, Grando-Lemaire V, Trinchet JC, Beaugrand M.

Clin Gastroenterol Hepatol. 2006 Aug;4(8):1062-8. Epub 2006 Jul 14.

PMID:
16844421
8.

Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data.

Trépo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke HD, Hamza S, Corradini SG, Burza MA, Guyot E, Donati B, Spengler U, Hillon P, Toniutto P, Henrion J, Franchimont D, Devière J, Mathurin P, Moreno C, Romeo S, Deltenre P.

Hepatology. 2014 Jun;59(6):2170-7. doi: 10.1002/hep.26767. Epub 2014 Apr 25.

PMID:
24114809
9.

PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma.

Valenti L, Motta BM, Soardo G, Iavarone M, Donati B, Sangiovanni A, Carnelutti A, Dongiovanni P, Rametta R, Bertelli C, Facchetti F, Colombo M, Fargion S, Fracanzani AL.

PLoS One. 2013 Oct 14;8(10):e75982. doi: 10.1371/journal.pone.0075982. eCollection 2013.

10.

A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis.

Nahon P, Sutton A, Rufat P, Charnaux N, Mansouri A, Moreau R, Ganne-Carrié N, Grando-Lemaire V, N'Kontchou G, Trinchet JC, Pessayre D, Beaugrand M.

J Hepatol. 2012 Feb;56(2):426-32. doi: 10.1016/j.jhep.2011.08.010. Epub 2011 Sep 8.

PMID:
21907168
11.

PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals.

Burza MA, Pirazzi C, Maglio C, Sjöholm K, Mancina RM, Svensson PA, Jacobson P, Adiels M, Baroni MG, Borén J, Ginanni Corradini S, Montalcini T, Sjöström L, Carlsson LM, Romeo S.

Dig Liver Dis. 2012 Dec;44(12):1037-41. doi: 10.1016/j.dld.2012.05.006. Epub 2012 Jun 15.

PMID:
22704398
12.

The adiponutrin I148M variant is a risk factor for HCV-associated liver cancer in North-African patients.

Ezzikouri S, Alaoui R, Tazi S, Nadir S, Elmdaghri N, Pineau P, Benjelloun S.

Infect Genet Evol. 2014 Jan;21:179-83. doi: 10.1016/j.meegid.2013.11.005. Epub 2013 Nov 20.

PMID:
24269995
13.

A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection.

Ali M, Yopp A, Gopal P, Beg MS, Zhu H, Lee W, Singal AG.

Clin Gastroenterol Hepatol. 2016 Feb;14(2):295-300. doi: 10.1016/j.cgh.2015.08.018. Epub 2015 Aug 21.

PMID:
26305067
14.

PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis.

Falleti E, Cussigh A, Cmet S, Fabris C, Toniutto P.

Dig Liver Dis. 2016 Jan;48(1):69-75. doi: 10.1016/j.dld.2015.09.009. Epub 2015 Sep 28.

PMID:
26493626
15.

Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis.

Nahon P, Sutton A, Rufat P, Ziol M, Akouche H, Laguillier C, Charnaux N, Ganne-Carrié N, Grando-Lemaire V, N'Kontchou G, Trinchet JC, Gattegno L, Pessayre D, Beaugrand M.

Hepatology. 2009 Nov;50(5):1484-93. doi: 10.1002/hep.23187.

PMID:
19731237
16.

Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C.

Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S.

Hepatology. 2011 Mar;53(3):791-9. doi: 10.1002/hep.24123. Epub 2011 Feb 11.

PMID:
21319195
17.

PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis.

Trepo E, Guyot E, Ganne-Carrie N, Degre D, Gustot T, Franchimont D, Sutton A, Nahon P, Moreno C.

Hepatology. 2012 Apr;55(4):1307-8. doi: 10.1002/hep.25518. No abstract available.

PMID:
22162034
18.

Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.

Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, Lobello S, Farinati F, Naccarato R.

Cancer. 1999 May 15;85(10):2132-7.

PMID:
10326690
19.

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.

Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, Ganne-Carrie N, Grando-Lemaire V, Trinchet JC, Gordien E, Vicaut E, Baghad I, Beaugrand M.

J Viral Hepat. 2011 Oct;18(10):e516-22. doi: 10.1111/j.1365-2893.2011.01441.x.

PMID:
21914071
20.

Association of PNPLA3 Polymorphism with Hepatocellular Carcinoma Development and Prognosis in Viral and Non-Viral Chronic Liver Diseases.

Khlaiphuengsin A, Kiatbumrung R, Payungporn S, Pinjaroen N, Tangkijvanich P.

Asian Pac J Cancer Prev. 2015;16(18):8377-82.

Supplemental Content

Support Center